Glaukos Corp Stock Today
| GKOS Stock | USD 156.39 0.12 0.08% |
Performance9 of 100
| Odds Of DistressLess than 9
|
Glaukos Corp is selling for under 156.39 as of the 18th of January 2025; that is 0.08% down since the beginning of the trading day. The stock's lowest day price was 153.68. Glaukos Corp has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat ok performance during the last 90 days. The performance scores are derived for the period starting the 24th of January 2024 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 25th of June 2015 | Category Healthcare | Classification Health Care |
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California. The company has 55.14 M outstanding shares of which 3.04 M shares are currently shorted by private and institutional investors with about 4.86 trading days to cover. More on Glaukos Corp
Moving together with Glaukos Stock
Moving against Glaukos Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Glaukos Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman | Thomas Burns | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NYSE Composite, SP Small-Cap 600, Health Care, Health Care Equipment & Supplies, Medical Devices, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGlaukos Corp can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Glaukos Corp's financial leverage. It provides some insight into what part of Glaukos Corp's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Glaukos Corp (GKOS) is traded on New York Stock Exchange in USA. It is located in One Glaukos Way, Aliso Viejo, CA, United States, 92656 and employs 907 people. Glaukos Corp is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 8.63 B. Glaukos Corp conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 55.14 M outstanding shares of which 3.04 M shares are currently shorted by private and institutional investors with about 4.86 trading days to cover.
Glaukos Corp currently holds about 391.19 M in cash with (57.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22.
Check Glaukos Corp Probability Of Bankruptcy
Ownership AllocationThe majority of Glaukos Corp outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Glaukos Corp to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Glaukos Corp. Please pay attention to any change in the institutional holdings of Glaukos Corp as this could imply that something significant has changed or is about to change at the company.
Check Glaukos Ownership Details
Glaukos Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-09-30 | 1.2 M | |
| Fred Alger Management, Llc | 2024-09-30 | 1.1 M | |
| Driehaus Capital Management Llc | 2024-09-30 | 861.6 K | |
| Artisan Partners Limited Partnership | 2024-09-30 | 795.2 K | |
| Loomis, Sayles & Company Lp | 2024-09-30 | 673.8 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 662.5 K | |
| Gilder Gagnon Howe & Co Llc | 2024-09-30 | 658.6 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 641.8 K | |
| Summit Partners Public Asset Management, Llc | 2024-09-30 | 617.4 K | |
| Blackrock Inc | 2024-09-30 | 8.5 M | |
| Fmr Inc | 2024-09-30 | 6.6 M |
Glaukos Corp Historical Income Statement
Glaukos Stock Against Markets
Glaukos Corp Corporate Directors
| Gilbert Kliman | Independent Director | Profile | |
| Mark Foley | Lead Independent Director | Profile | |
| Aimee Weisner | Independent Director | Profile | |
| David Hoffmeister | Independent Director | Profile |
Additional Tools for Glaukos Stock Analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.